Teva Pharmaceutical Industries Limited (NYSE: TEVA) has been identified as one of the best performing pharma stocks in 2025. Truist raised the price target on TEVA to $36 from $32 on January 7, maintaining a Buy rating due to the attractiveness of the affordable medicines theme. S&P Global Ratings upgraded TEVA’s long-term issuer credit rating to ‘BB+’ from ‘BB’ with a stable outlook, marking a milestone in the company’s journey towards investment-grade status. Teva’s business strength, liquidity profile, and financial discipline have contributed to a rebound in revenue growth, supported by solid performance in branded medicines and stabilization in generics.

Read more at Yahoo Finance: Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32